These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 3707148)

  • 1. [Toxic effects of cisplatin in the treatment of malignant bone and soft tissue tumors].
    Umeda T; Takada N; Hodaka E; Endoh F; Ishii T
    Gan To Kagaku Ryoho; 1986 May; 13(5):1857-61. PubMed ID: 3707148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemotherapy using cisplatin in bone and soft tissue sarcoma].
    Isu K; Goto M; Yamawaki S; Ubayama Y
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):100-4. PubMed ID: 3467652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cis-dichlorodiammineplatinum(II) in advanced soft tissue and bony sarcomas: a Southwest Oncology Group Study.
    Samson MK; Baker LH; Benjamin RS; Lane M; Plager C
    Cancer Treat Rep; 1979; 63(11-12):2027-9. PubMed ID: 575067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
    Ishii T; Umeda T; Kitoh M; Tatezaki S; Satoh T
    Gan To Kagaku Ryoho; 1993 Mar; 20(4):509-14. PubMed ID: 8452388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of myocutaneous adverse side effect due to intra-arterial chemotherapy by intra-arterial (99m)Tc-macroaggregated albumin administration in patients with bone and soft-tissue tumors.
    Taki J; Sumiya H; Higuchi T; Tsuchiya H; Takazawa K; Tomita K; Tonami N
    J Nucl Med; 2002 Nov; 43(11):1452-6. PubMed ID: 12411547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
    Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
    Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.
    Reddel RR; Kefford RF; Grant JM; Coates AS; Fox RM; Tattersall MH
    Cancer Treat Rep; 1982 Jan; 66(1):19-23. PubMed ID: 7198012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
    Budd GT; Metch B; Weiss SA; Weick JK; Fabian C; Stephens RL; Balcerzak SP
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S213-6. PubMed ID: 8453701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
    Tanimura S; Banba J; Tomoyasu H; Masaki M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [High dose cisplatin combination chemotherapy for advanced breast cancer--a report on 50 cases].
    Zhou JC
    Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):215-7. PubMed ID: 8261870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report.
    Baum ES; Gaynon P; Greenberg L; Krivit W; Hammond D
    Cancer Treat Rep; 1981; 65(9-10):815-22. PubMed ID: 6944156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin vestibular ototoxicity: preliminary report.
    Black FO; Myers EN; Schramm VL; Johnson J; Sigler B; Thearle PB; Burns DS
    Laryngoscope; 1982 Dec; 92(12):1363-8. PubMed ID: 6983636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ototoxicity following the administration of high doses of cisplatin in children with malignant neoplasms].
    Stura M; Perin GP; Dini G; Dallorso S; Squazzini G; Tacchino A; Tarantino V; De Bernardi B
    Pediatr Med Chir; 1985; 7(6):851-4. PubMed ID: 3837255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
    Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recovery from cisplatin-induced ototoxicity: a case report and review.
    Truong MT; Winzelberg J; Chang KW
    Int J Pediatr Otorhinolaryngol; 2007 Oct; 71(10):1631-8. PubMed ID: 17706797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. History of testicular cancer chemotherapy: maximizing efficacy, minimizing toxicity.
    Sweeney C
    Semin Urol Oncol; 2001 Aug; 19(3):170-9. PubMed ID: 11561984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary phase I clinical study and pharmacokinetics of (1,2-diaminocyclohexane) (isocitrato) platinum (II) or PHIC.
    Gouyette A; Ducret JP; Caillé P; Amiel JL; Rouëssé J; Foka M; Carde P; Hayat M; Sancho-Garnier H
    Anticancer Res; 1986; 6(5):1127-32. PubMed ID: 3800320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxic effects of cis-dichlorodiammineplatinum(II) in man.
    Von Hoff DD; Schilsky R; Reichert CM; Reddick RL; Rozencweig M; Young RC; Muggia FM
    Cancer Treat Rep; 1979; 63(9-10):1527-31. PubMed ID: 387223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.